How will tovorafenib change our treatment of pediatric low-grade glioma?
Expert Opin Emerg Drugs. 2024 Jan 31:1-3. doi: 10.1080/14728214.2024.2312817. Online ahead of print.NO ABSTRACTPMID:38293894 | DOI:10.1080/14728214.2024.2312817 (Source: Expert Opinion on Emerging Drugs)
Source: Expert Opinion on Emerging Drugs - January 31, 2024 Category: Drugs & Pharmacology Authors: Inci Yaman Eric Bouffet Source Type: research
Emerging drugs for the treatment of irritability associated with autism spectrum disorder
Expert Opin Emerg Drugs. 2024 Jan 31:1-12. doi: 10.1080/14728214.2024.2313650. Online ahead of print.ABSTRACTINTRODUCTION: Autism spectrum disorder (ASD) is an early-onset disorder with a prevalence of 1% among children and reported disability-adjusted life years of 4.31 million. Irritability is a challenging behavior associated with ASD, for which medication development has lagged. More specifically, pharmacotherapy effectiveness may be limited against high adverse effects (considering side effect profiles and patient medication sensitivity); thus, the possible benefits of pharmacological interventions must be balanced ag...
Source: Expert Opinion on Emerging Drugs - January 31, 2024 Category: Drugs & Pharmacology Authors: Ahmad Shamabadi Hanie Karimi Razman Arabzadeh Bahri Mohsen Motavaselian Shahin Akhondzadeh Source Type: research
Cannabinoid treatment for the symptoms of autism spectrum disorder
Expert Opin Emerg Drugs. 2024 Jan 16:1-15. doi: 10.1080/14728214.2024.2306290. Online ahead of print.ABSTRACTINTRODUCTION: Autism spectrum disorder (ASD) is a neurodevelopmental disorder affecting approximately 3% of school-age children. The core symptoms are deficits in social communication and restricted and repetitive patterns of behavior. Associated problems in cognition, language, behavior, sleep and mood are prevalent. Currently, no established pharmacological treatment exists for core ASD symptoms. Risperidone and aripiprazole are used to manage associated irritability, but their effectiveness is limited and adverse...
Source: Expert Opinion on Emerging Drugs - January 16, 2024 Category: Drugs & Pharmacology Authors: Adi Aran Dalit Cayam Rand Source Type: research
Novel and emerging drugs for the treatment of Crohn's disease: a review of phase II and III trials
Expert Opin Emerg Drugs. 2024 Jan 9:1-16. doi: 10.1080/14728214.2024.2303116. Online ahead of print.ABSTRACTINTRODUCTION: Crohn's disease (CD) is a chronic inflammatory bowel disease characterized by unpredictable flare-ups and periods of remission. While several therapeutic options, such as anti-tumor necrosis factor (TNF), anti-integrin, and interleukin (IL) 12/23 inhibitors, as well as IL-23 and Janus kinase (JAK) inhibitors, have been approved for CD treatment, a substantial number of patients fail to respond adequately or experience a loss of response over time. In recent years, the scientific community has been activ...
Source: Expert Opinion on Emerging Drugs - January 9, 2024 Category: Drugs & Pharmacology Authors: Panu Wetwittayakhlang Talat Bessissow Peter L Lakatos Source Type: research
How promising are the latest monoclonal antibodies targeting amyloid- β for the treatment of early Alzheimer's disease?
Expert Opin Emerg Drugs. 2024 Jan 9:1-9. doi: 10.1080/14728214.2024.2304059. Online ahead of print.ABSTRACTINTRODUCTION: Monoclonal antibodies targeting amyloid-β are the first disease-modifying treatments for Alzheimer disease to have received FDA-approval. There are three different drugs approved or pending FDA-approval: aducanumab, lecanemab, and donanemab. These three drugs are each in different stages of regulatory approval by the FDA.AREAS COVERED: We discuss the development of these drugs, the data regarding their clinical efficacy, their dosing regimens, and side effects. In addition, we examine pragmatic issues w...
Source: Expert Opinion on Emerging Drugs - January 9, 2024 Category: Drugs & Pharmacology Authors: Jordan Beveridge Eileen Kaniecki Aniketh Naidu Bret David Silverglate George Grossberg Source Type: research
Novel and emerging drugs for the treatment of Crohn's disease: a review of phase II and III trials
Expert Opin Emerg Drugs. 2024 Jan 9. doi: 10.1080/14728214.2024.2303116. Online ahead of print.ABSTRACTINTRODUCTION: Crohn's disease (CD) is a chronic inflammatory bowel disease characterized by unpredictable flare-ups and periods of remission. While several therapeutic options, such as anti-tumor necrosis factor (TNF), anti-integrin, and interleukin (IL) 12/23 inhibitors, as well as IL-23 and Janus kinase (JAK) inhibitors, have been approved for CD treatment, a substantial number of patients fail to respond adequately or experience a loss of response over time. In recent years, the scientific community has been actively i...
Source: Expert Opinion on Emerging Drugs - January 9, 2024 Category: Drugs & Pharmacology Authors: Panu Wetwittayakhlang Talat Bessissow Peter L Lakatos Source Type: research
How promising are the latest monoclonal antibodies targeting amyloid- β for the treatment of early Alzheimer's disease?
Expert Opin Emerg Drugs. 2024 Jan 9. doi: 10.1080/14728214.2024.2304059. Online ahead of print.ABSTRACTINTRODUCTION: Monoclonal antibodies targeting amyloid-β are the first disease-modifying treatments for Alzheimer disease to have received FDA-approval. There are three different drugs approved or pending FDA-approval: aducanumab, lecanemab, and donanemab. These three drugs are each in different stages of regulatory approval by the FDA.AREAS COVERED: We discuss the development of these drugs, the data regarding their clinical efficacy, their dosing regimens, and side effects. In addition, we examine pragmatic issues with ...
Source: Expert Opinion on Emerging Drugs - January 9, 2024 Category: Drugs & Pharmacology Authors: Jordan Beveridge Eileen Kaniecki Aniketh Naidu Bret David Silverglate George Grossberg Source Type: research
Review of phase 2/3 trials in Polymyalgia Rheumatica and giant cell arteritis
Expert Opin Emerg Drugs. 2024 Jan 5. doi: 10.1080/14728214.2024.2303093. Online ahead of print.ABSTRACTINTRODUCTION: GCA (Giant cell arteritis) and PMR (Polymyalgia Rheumatica) are two overlapping inflammatory rheumatic conditions that are seen exclusively in older adults, sharing some common features. GCA is a clinical syndrome characterized by inflammation of the medium and large arteries, with both cranial and extracranial symptoms. PMR is a clinical syndrome characterized by stiffness in the neck, shoulder and pelvic girdle muscles. Both are associated with constitutional symptoms.AREAS COVERED: In this review, we asse...
Source: Expert Opinion on Emerging Drugs - January 5, 2024 Category: Drugs & Pharmacology Authors: Pratheeshaa Nageswaran Saad Ahmed Hasan Tahir Source Type: research
Recent advances in uveitis therapy: focus on selected phase 2 and 3 clinical trials
Expert Opin Emerg Drugs. 2023 Dec;28(4):297-309. doi: 10.1080/14728214.2023.2293049. Epub 2023 Dec 26.ABSTRACTINTRODUCTION: Uveitis is a heterogeneous group of ocular conditions characterized by inflammation of the uveal tract. It is a leading cause of blindness in developed countries and exerts significant psychological, social, and economic impact on both patients and the larger society. While there are numerous pharmacotherapy options, posterior segment noninfectious uveitis remains a significant challenge to treat due to its severity, chronicity, and high recurrence rates.AREAS COVERED: The index review highlights the ...
Source: Expert Opinion on Emerging Drugs - December 22, 2023 Category: Drugs & Pharmacology Authors: Zheng Xian Thng Albert John Bromeo S Saeed Mohammadi Anadi Khatri Anh N T Tran Amir Akhavanrezayat Ngoc T T Than Khiem S Nguyen Woong-Sun Yoo Azadeh Mobasserian Christopher Chi Mong Or Quan Dong Nguyen Source Type: research
